CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease - PubMed (original) (raw)
CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease
Mika Shimoji et al. Neurotox Res. 2009 Oct.
Abstract
Except for a handful of inherited cases related to known gene defects, Parkinson's disease (PD) is a sporadic neurodegenerative disease of unknown etiology. There is increasing evidence that inflammation and proliferation of microglia may contribute to the neuronal damage seen in the nigro-striatal dopaminergic system of PD patients. Microglia events that participate in neuronal injury include the release of pro-inflammatory and neurotoxic factors. Characterizing these factors may help to prevent the exacerbation of PD symptoms or to remediate the disease progression. In rodents, the nigro-striatal system exhibits high expression of the chemokine receptor CXCR4. Its natural ligand CXCL12 can promote neuronal apoptosis. Therefore, the present study investigated the expression of CXCR4 and CXCL12 in post-mortem brains of PD and control (non-PD) individuals and in an animal model of PD. In the human substantia nigra (SN), CXCR4 immunoreactivity was high in dopaminergic neurons. Interestingly, the SN of PD subjects exhibited higher expression of CXCR4 expression and CXCL12 than control subjects despite the loss of dopamine (DA) neurons. This effect was accompanied by an increase in activated microglia. However, results from post-mortem brains may not provide indication as to whether CXCL12/CXCR4 can cause the degeneration of DA neurons. To examine the role of these chemokines, we determined the levels of CXCL12 and CXCR4 in the SN of MPTP-treated mice. MPTP produced a time-dependent up-regulation of CXCR4 that preceded the loss of DA neurons. These results suggest that CXCL12/CXCR4 may participate in the etiology of PD and indicate a new possible target molecule for PD.
Similar articles
- EphA1 Activation Induces Neuropathological Changes in a Mouse Model of Parkinson's Disease Through the CXCL12/CXCR4 Signaling Pathway.
Ma J, Wang Z, Chen S, Sun W, Gu Q, Li D, Zheng J, Yang H, Li X. Ma J, et al. Mol Neurobiol. 2021 Mar;58(3):913-925. doi: 10.1007/s12035-020-02122-x. Epub 2020 Oct 15. Mol Neurobiol. 2021. PMID: 33057926 - Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.
Parillaud VR, Lornet G, Monnet Y, Privat AL, Haddad AT, Brochard V, Bekaert A, de Chanville CB, Hirsch EC, Combadière C, Hunot S, Lobsiger CS. Parillaud VR, et al. J Neuroinflammation. 2017 Mar 21;14(1):60. doi: 10.1186/s12974-017-0830-9. J Neuroinflammation. 2017. PMID: 28320442 Free PMC article. - Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV, Morgan WW, Sigala J, Maffi SK, Condello C, Kuziel W, Ahuja SS, Ahuja SK. Kalkonde YV, et al. Brain Res. 2007 Jan 12;1128(1):1-11. doi: 10.1016/j.brainres.2006.08.041. Epub 2006 Nov 28. Brain Res. 2007. PMID: 17126305 - Role of cytokines in inflammatory process in Parkinson's disease.
Sawada M, Imamura K, Nagatsu T. Sawada M, et al. J Neural Transm Suppl. 2006;(70):373-81. doi: 10.1007/978-3-211-45295-0_57. J Neural Transm Suppl. 2006. PMID: 17017556 Review. - Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.
Nagatsu T, Sawada M. Nagatsu T, et al. J Neural Transm Suppl. 2007;(72):113-20. doi: 10.1007/978-3-211-73574-9_14. J Neural Transm Suppl. 2007. PMID: 17982884 Review.
Cited by
- When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration?
Mocchetti I, Campbell LA, Harry GJ, Avdoshina V. Mocchetti I, et al. J Neuroimmune Pharmacol. 2013 Mar;8(1):118-31. doi: 10.1007/s11481-012-9353-4. Epub 2012 Apr 15. J Neuroimmune Pharmacol. 2013. PMID: 22527632 Free PMC article. Review. - SDF-1α and LPA modulate microglia potassium channels through rho gtpases to regulate cell morphology.
Muessel MJ, Harry GJ, Armstrong DL, Storey NM. Muessel MJ, et al. Glia. 2013 Oct;61(10):1620-8. doi: 10.1002/glia.22543. Epub 2013 Jul 25. Glia. 2013. PMID: 23893870 Free PMC article. - Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.
Rocha NP, Scalzo PL, Barbosa IG, Souza MS, Morato IB, Vieira EL, Christo PP, Teixeira AL, Reis HJ. Rocha NP, et al. Parkinsons Dis. 2014;2014:903796. doi: 10.1155/2014/903796. Epub 2014 Oct 15. Parkinsons Dis. 2014. PMID: 25386381 Free PMC article. - CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
Chung YC, Shin WH, Baek JY, Cho EJ, Baik HH, Kim SR, Won SY, Jin BK. Chung YC, et al. Exp Mol Med. 2016 Jan 22;48(1):e205. doi: 10.1038/emm.2015.100. Exp Mol Med. 2016. PMID: 27534533 Free PMC article. - Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson's Disease: a Systematic Review.
Dos Santos MG, Schimith LE, André-Miral C, Muccillo-Baisch AL, Arbo BD, Hort MA. Dos Santos MG, et al. Neurotox Res. 2022 Feb;40(1):319-345. doi: 10.1007/s12640-021-00450-x. Epub 2022 Jan 11. Neurotox Res. 2022. PMID: 35013904 Review.
References
- J Neuroimmunol. 2002 Jun;127(1-2):115-26 - PubMed
- Exp Mol Pathol. 2000 Dec;69(3):192-201 - PubMed
- Neurotox Res. 2007 Sep;12(2):135-43 - PubMed
- Eur J Neurosci. 2008 Sep;28(5):862-70 - PubMed
- Glia. 1993 Jan;7(1):60-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical